Page last updated: 2024-10-23

bethanechol and Scleroderma, Systemic

bethanechol has been researched along with Scleroderma, Systemic in 3 studies

Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.
bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.

Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.

Research Excerpts

ExcerptRelevanceReference
"Patients with systemic sclerosis (SSc) have impairments in gastrointestinal smooth muscle function."1.38Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. ( Cohen, S; Dimarino, AJ; Jimenez, SA; Mehendiratta, V; Mendoza, F; Rattan, S; Singh, J, 2012)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Singh, J2
Mehendiratta, V2
Del Galdo, F1
Jimenez, SA2
Cohen, S2
DiMarino, AJ2
Rattan, S2
Mendoza, F1
Rees, WD1
Leigh, RJ1
Christofides, ND1
Bloom, SR1
Turnberg, LA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Precision Medicine in Systemic Sclerosis Gastrointestinal Disease: Evaluating Imaging and Stool Biomarkers for Differentiating Disease Stages and Treatment Responses[NCT04630782]70 participants (Anticipated)Observational2020-04-09Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for bethanechol and Scleroderma, Systemic

ArticleYear
Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.
    American journal of physiology. Gastrointestinal and liver physiology, 2009, Volume: 297, Issue:6

    Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anal Canal; Animals; Autoantibodies; Benz

2009
Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function.
    Gastroenterology, 2012, Volume: 143, Issue:5

    Topics: Acetylcholine; Anal Canal; Animals; Autoantibodies; Bethanechol; Colon; Female; Humans; Immunoglobul

2012
Interdigestive motor activity in patients with systemic sclerosis.
    Gastroenterology, 1982, Volume: 83, Issue:3

    Topics: Adult; Bethanechol; Bethanechol Compounds; Duodenum; Fasting; Female; Gastrointestinal Motility; Hum

1982